Facial Injectable Market Share, Size, Trends, Industry Analysis Report, By Product (Collagen & PMMA Microspheres, Botulinum Toxin Type A, Hyaluronic Acid (HA), Calcium Hydroxylapatite (CaHA), Poly-L-lactic Acid (PLLA), and Others); By Application; By End-

Facial Injectable Market Share, Size, Trends, Industry Analysis Report, By Product (Collagen & PMMA Microspheres, Botulinum Toxin Type A, Hyaluronic Acid (HA), Calcium Hydroxylapatite (CaHA), Poly-L-lactic Acid (PLLA), and Others); By Application; By End-use; By Region; Segment Forecast, 2024 - 2032

The global facial injectable market size is expected to reach USD 33.56 billion by 2032, according to a new study by Polaris Market Research. The report “Facial Injectable Market Share, Size, Trends, Industry Analysis Report, By Product (Collagen & PMMA Microspheres, Botulinum Toxin Type A, Hyaluronic Acid (HA), Calcium Hydroxylapatite (CaHA), Poly-L-lactic Acid (PLLA), and Others); By Application; By End-use; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Key drivers augmenting the demand for facial injectables include rapidly developing healthcare infrastructure, rising disposable income of the population, and an increase in regulatory approvals of facial injectables.

For instance, in May 2023, AbbVie announced the FDA approval of Juvederm's Skinvive to improve skin smoothness in cheeks.

The increase in awareness about minimally invasive procedures, rising cases of facial wrinkles, and loss of facial volume also favor the expansion of the facial injectable market across the globe. The shift in consumer preference for injectable procedures, owing to faster results, convenience, and affordability, has enhanced the market growth.

Facial injectables can be ideally used to treat certain types of acne scars, restore facial fat loss, increase fullness of lips, enhance facial contours, and smooth wrinkles and creases. Moreover, the minimal recovery time of the procedure will increase the facial injectable market growth. For instance, according to the report published by the American Society of Plastic Surgeons Procedural Statistics Release, rhinoplasty, also known as nose re-shaping, accounted for a 37% increase from 32,484 procedures in 2019 to 44,503 procedures in 2022.

Companies in the marketplace are introducing new innovative products to maintain their market share. For instance, in January 2023, Allergan Aesthetics introduced JUVEDERM VOLUX for the correction of moderate to severe facial wrinkles and folds. Similarly, in November 2023, Merz Aesthetics introduced their hyaluronic acid dermal filler, BELOTERO VOLUME, in China. Furthermore, the significant increase in the number of regulatory approvals for commercializing products is also bolstering the market growth. For instance, in June 2023, Galderma announced the FDA approval of Restylane Eyelight, an under-eye hyaluronic acid (HA) dermal filler.

Facial Injectable Market Report Highlights

The Hyaluronic Acid (HA) segment will grow rapidly, attributed to its versatility, efficacy, and minimally invasive nature of the product.

The Facial line correction segment accounted for the largest market share, owing to the rapid growth of aging population across the globe.

The MedSpa segment dominated the market, due to the surge in demand for cosmetic procedures.

North America dominated the market, owing to the rise in awareness related to the benefits of facial injectables.

The global players include Allergan Aesthetics (Abbvie Inc.), GALDERMA, Merz Pharma, Zimmer Aesthetics, and Teoxane.

Polaris Market Research has segmented the facial injectable market report based on product, application, end-use, and region:

Facial Injectable, Product Outlook (Revenue - USD Billion, 2019 - 2032)

Collagen & PMMA Microspheres

Botulinum Toxin Type A

Hyaluronic Acid (HA)

Calcium Hydroxylapatite (CaHA)

Poly-L-lactic Acid (PLLA)

Others

Facial Injectable, Application Outlook (Revenue - USD Billion, 2019 - 2032)

Facial Line Correction

Lip Augmentation

Face Lift

Acne Scar Treatment

Lipoatrophy Treatment

Others

Facial Injectable, End-use Outlook (Revenue - USD Billion, 2019 - 2032)

MedSpa

Dermatology Clinics

Hospitals

Facial Injectable, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Rest of Europe

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Australia

Rest of Asia Pacific

Latin America

Argentina

Brazil

Mexico

Rest of Latin America

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Rest of Middle East & Africa
Show more